Ameritas Investment Partners’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Ameritas Investment Partners’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-670	Closed	-$5K	–	3309
2021 Q1	$5K	Hold	670	–	–	﹤0.01%	3017
2020 Q4	$5K	Hold	670	–	–	﹤0.01%	2986
2020 Q3	$6K	Hold	670	–	–	﹤0.01%	2952
2020 Q2	$6K	Hold	670	–	–	﹤0.01%	2937
2020 Q1	$3K	Hold	670	–	–	﹤0.01%	2940
2019 Q4	$5K	Hold	670	–	–	﹤0.01%	2909
2019 Q3	$7K	Hold	670	–	–	﹤0.01%	2870
2019 Q2	$9K	Hold	670	–	–	﹤0.01%	2843
2019 Q1	$7K	Hold	670	–	–	﹤0.01%	2811
2018 Q4	$7K	Buy	+670	New	+$8.09K	﹤0.01%	2794

Other funds holding LOGC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Ameritas Investment Partners's LOGC Position: Q2 2021 in Review

Ameritas Investment Partners sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2021, closing a stake of 670 shares — an estimated $5K sold.

Ameritas Investment Partners first reported a position in LOGC in Q4 2018 and held it in 10 quarters. The position peaked at $9K in Q2 2019. 63 funds tracked by Wall St. Rank hold LOGC as of Q2 2021.

Ameritas Investment Partners reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Ameritas Investment Partners sold 670 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $5K.
Ameritas Investment Partners first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 10 quarters.
Ameritas Investment Partners's LogicBio Therapeutics, Inc. Common Stock position peaked at $9K in Q2 2019.
63 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.